Compare AbCellera Biologics Inc (ABCL) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? AbCellera Biologics Inc trades at $10.26 (market cap $2.99B), while iShares Core MSCI Emerging Markets ETF trades at $81.17. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | IEMG | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $9.76 | $86.00 |
52-Week Low | $2.78 | $61.76 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
IEMG trades at $81.02, up 1.84% today with a bullish technical signal from moving averages. The ETF shows strong momentum with 35% returns over the past year, driven by emerging market exposure and a 40% technology weighting focused on AI themes. Recent news highlights IEMG's outperformance versus developed market ETFs and its competitive 0.09% expense ratio.
Outlook remains positive given emerging market growth potential and AI-driven tech exposure, though risks include concentration in volatile emerging economies and elevated RSI levels suggesting potential near-term consolidation. The ETF's valuation discount to US equities and strong institutional inflows support continued investor interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
